<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740529</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-BTK-18001 (BRUIN)</org_study_id>
    <nct_id>NCT03740529</nct_id>
  </id_info>
  <brief_title>A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL</brief_title>
  <official_title>A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 in patients with CLL/SLL&#xD;
      and NHL who have failed or are intolerant to standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes 3 parts: phase 1 (LOXO-305 monotherapy dose escalation and dose&#xD;
      expansion), phase 1b (LOXO-305 combination therapy dose expansion), and phase 2 (LOXO-305&#xD;
      monotherapy dose expansion). In phase 1, patients will be enrolled using an accelerated&#xD;
      titration design. The starting dose of LOXO-305 in oral tablet form is 25 mg/day (e.g., 25 mg&#xD;
      once daily [QD]). Once the MTD and/or RP2D is identified in phase 1 dose escalation,&#xD;
      enrollment will continue to phase 1 dose expansion and can commence to phase 1b (Arms A and&#xD;
      B). For phase 2, patients will be enrolled to one of seven phase 2 dose expansion cohorts&#xD;
      depending on tumor histology and prior treatment history. Cycle length will be 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended dose for further study</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the preliminary anti-tumor activity of LOXO-305 based on ORR as assessed by an Independent Review Committee (IRC).</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Phase II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of LOXO-305 in combination with venetoclax (Arm A) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>For Phase 1b</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety of LOXO-305 in combination with venetoclax and rituximab (Arm B) by assessing incidence and severity of treatment-emergent adverse events as determined by CTCAE v5.0</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>For Phase 1b</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety profile and tolerability of LOXO-305 including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) properties of LOXO-305 by collecting and evaluating serum at protocol specified time points.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of LOXO-305 based on overall response rate (ORR) as assessed by investigator.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR as assessed by the Investigator.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR) as assessed by the Investigator and IRC.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as assessed by the Investigator and IRC.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) as assessed by the Investigator and IRC.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS).</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety profile and tolerability of LOXO-305 including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) properties of LOXO-305 by collecting and evaluating serum at protocol specified time points.</measure>
    <time_frame>Up to 24 Months</time_frame>
    <description>Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) properties of LOXO-305 by collecting and evaluating serum at protocol specified time points.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>For Phase 1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of LOXO-305 in combination based on overall response rate (ORR) as assessed by investigator.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>For Phase 1b</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Response: Change from Baseline in Mantle Cell Lymphoma (MCL)-related symptoms selected from the European Organisation for Research and Treatment of Cancer (EORTC) Item Library</measure>
    <time_frame>Baseline, End of Treatment (Estimated Up to 24 Months)</time_frame>
    <description>Individual EORTC symptom scores range from 1 (not at all) to 4 (very much) with higher scores representing more severe symptom severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Response: Change from Baseline in Physical Functioning as Measured by Physical Functioning Scale from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Version 3.0 (EORTC QLQ)</measure>
    <time_frame>Baseline, End of Treatment (Estimated Up to 24 Months)</time_frame>
    <description>EORTC physical function item scores range from 1 (not at all) to 4 (very much) with higher scores indicating poorer functioning.The total EORTC physical functioning score ranges from 0-100 where a higher score indicates higher/healthier level of functioning.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">860</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>B-cell Lymphoma</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase I Dose Escalation (LOXO-305) Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and determination of MTD; multiple dose levels of LOXO-305 to be evaluated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL/SLL patients with no prior therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>WM patients treated with a prior BTK inhibitor-containing regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MZL patients treated with a prior BTK inhibitor-containing regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Not otherwise specified) Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late Phase studies of LOXO-305 would remain eligible to enroll in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax and Rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose Expansion (LOXO-305 Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients to receive the recommended Phase 2 dose of LOXO-305.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-305</intervention_name>
    <description>Oral LOXO-305</description>
    <arm_group_label>Phase 1 Dose Expansion (LOXO-305 Monotherapy)</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B</arm_group_label>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 1</arm_group_label>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 2</arm_group_label>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 3</arm_group_label>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 4</arm_group_label>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 5</arm_group_label>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 6</arm_group_label>
    <arm_group_label>Phase 2 (LOXO-305 Monotherapy) Cohort 7</arm_group_label>
    <arm_group_label>Phase I Dose Escalation (LOXO-305) Monotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Oral</description>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A</arm_group_label>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B</arm_group_label>
    <other_name>Venclexta, Venclyxto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>IV</description>
    <arm_group_label>Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed CLL/SLL, WM, or NHL intolerant to either ≥ 2 prior standard&#xD;
             of care regimens given in combination or sequentially OR have received 1 prior BTK&#xD;
             inhibitor-containing regimen when a BTK inhibitor is approved as first line therapy&#xD;
             (Phase 1) OR with prior treatment defined by phase 2 cohort (Phase 2 Patients only).&#xD;
&#xD;
          -  Adequate hematologic function (Phase 1 and 1b Patients only).&#xD;
&#xD;
          -  Responsive to transfusion support if given for thrombocytopenia or anemia (Phase 1 and&#xD;
             1b Patients only).&#xD;
&#xD;
          -  Histologically confirmed relapsed/recurrent CLL in whom venetoclax is appropriate&#xD;
             standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm A Patients&#xD;
             only).&#xD;
&#xD;
          -  Histologically confirmed relapsed/refractory CLL in whom venetoclax + rituximab is&#xD;
             appropriate standard salvage treatment; no prior venetoclax is permitted (Phase 1b Arm&#xD;
             B Patients only).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2.&#xD;
&#xD;
          -  Adequate hepatic and renal function.&#xD;
&#xD;
          -  Ability to receive study drug therapy orally.&#xD;
&#xD;
          -  Willingness of men and women of reproductive potential (defined as following menarche&#xD;
             and not postmenopausal [and 2 years of non-therapy-induced amenorrhea] or surgically&#xD;
             sterile) to observe conventional and effective birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigational agent or anticancer therapy within 5 half-lives prior to planned start&#xD;
             of specified study therapy except therapeutic monoclonal antibody treatment must be&#xD;
             discontinued a minimum of 4 weeks prior to the first dose of LOXO-305. In addition, no&#xD;
             concurrent systemic anticancer therapy is permitted.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to planned start of specified study therapy.&#xD;
&#xD;
          -  Radiotherapy with a limited field of radiation for palliation within 7 days of the&#xD;
             first dose of study treatment.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Patients requiring therapeutic anticoagulation with warfarin.&#xD;
&#xD;
          -  Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 2&#xD;
             or greater at the time of starting study treatment except for alopecia.&#xD;
&#xD;
          -  History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen&#xD;
             receptor-modified T-cell (CAR-T) therapy within the past 60 days (180 days before the&#xD;
             PK trigger) prior to planned start of specified study therapy.&#xD;
&#xD;
          -  Known central nervous system (CNS) involvement by systemic lymphoma. Patients with&#xD;
             previous treatment for CNS involvement who are neurologically stable and without&#xD;
             evidence of disease may be eligible and enrolled to phase 2 Cohort 7 if a compelling&#xD;
             clinical rationale is provided by the Investigator and with documented Sponsor&#xD;
             approval.&#xD;
&#xD;
          -  Active uncontrolled auto-immune cytopenia where new therapy introduced or concomitant&#xD;
             therapy escalated within the 4 weeks prior to study enrollment is required to maintain&#xD;
             adequate blood counts.&#xD;
&#xD;
          -  Clinically significant, uncontrolled cardiac, cardiovascular disease or history of&#xD;
             myocardial infarction within 6 months prior to planned start of LOXO-305.&#xD;
&#xD;
          -  Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.&#xD;
&#xD;
          -  Patients who have tested positive for Human Immunodeficiency Virus (HIV) are excluded.&#xD;
             For patients with unknown HIV status, HIV testing will be performed at Screening and&#xD;
             result should be negative for enrollment.&#xD;
&#xD;
          -  Clinically significant active malabsorption syndrome.&#xD;
&#xD;
          -  Current treatment with certain strong CYP3A4 inhibitors or inducers and/or strong P-gp&#xD;
             inhibitors.&#xD;
&#xD;
          -  For patients enrolled to phase 1b Arm A or B: Patients with prior treatment with&#xD;
             venetoclax or other BCL-2 inhibitors.&#xD;
&#xD;
          -  Prior treatment with LOXO-305.&#xD;
&#xD;
          -  Active second malignancy unless in remission and with life expectancy &gt; 2 years.&#xD;
&#xD;
          -  Known hypersensitivity to any component or excipient of LOXO-305.&#xD;
&#xD;
          -  For patients enrolled to phase 1b Arm B: Patients with prior significant&#xD;
             hypersensitivity, allergy, or anaphylactic reaction to rituximab/biosimilar requiring&#xD;
             discontinuation.&#xD;
&#xD;
          -  Patients with prior significant hypersensitivity to rituximab requiring&#xD;
             discontinuation, prior allergic or anaphylactic reaction to rituximab (Phase 1b Arm B&#xD;
             Patients only).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Tsai, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-855-LOXO-305</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic of Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scripps Coastal Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco, Medical Center at Paranassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale-New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists ORLANDO/DDU</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Durham VA Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpighi - Universita di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya Medical Center</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kochi Medical School Hospital</name>
      <address>
        <city>Nankoku</city>
        <state>Kochi</state>
        <zip>783-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyoto Furitsu Medical University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osakasayama-Shi</city>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instytut Hermatologii I Transfuzjologii</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Solna</city>
        <state>AB</state>
        <zip>171 65</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Bellinzona e Valli - Bellinzona</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>Pl6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loxo</keyword>
  <keyword>LOXO-305</keyword>
  <keyword>BTK</keyword>
  <keyword>Bruton's tyrosine kinase</keyword>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>NHL</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>C481S</keyword>
  <keyword>C481</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Acalabrutinib</keyword>
  <keyword>Zanubrutinib</keyword>
  <keyword>BGB-3111</keyword>
  <keyword>GS-4059</keyword>
  <keyword>ONO-4059</keyword>
  <keyword>Tirabrutinib</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>BTK Intolerant</keyword>
  <keyword>C481S Mutation</keyword>
  <keyword>Marginal zone lymphoma</keyword>
  <keyword>DLBCL (Diffuse Large B-cell lymphoma)</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>PI3KD</keyword>
  <keyword>Idelalisib</keyword>
  <keyword>Umbralisib</keyword>
  <keyword>BCL2</keyword>
  <keyword>Venetoclax</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Primary CNS Lymphoma</keyword>
  <keyword>Richter's Transformation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

